Profile data is unavailable for this security.
About the company
Aditxt, Inc. is a biotech company focused on discovering, developing, and deploying health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. It also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.
- Revenue in USD (TTM)645.19k
- Net income in USD-32.70m
- Incorporated2017
- Employees47.00
- LocationAditxt Inc737 N. Fifth Street, Suite 200RICHMOND 23219United StatesUSA
- Phone+1 (909) 488-0844
- Fax+1 (302) 697-4597
- Websitehttps://aditxt.com/
More ▼
Mergers & acquisitions
| Acquired company | ADTX:NAQ since announced | Transaction value |
|---|---|---|
| Evofem Biosciences Inc | -37.11% | 100.00m |
Data delayed at least 15 minutes, as of Apr 26 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Finch Therapeutics Group Inc | 107.00k | -74.75m | 3.73m | 18.00 | -- | 0.1628 | -- | 34.82 | -46.59 | -46.59 | 0.0667 | 14.25 | 0.001 | -- | 1.49 | -- | -68.48 | -- | -74.93 | -- | -- | -- | -69,863.55 | -- | -- | -- | 0.00 | -- | -87.57 | -- | 34.80 | -- | -- | -- |
| Applied DNA Sciences Inc | 9.00m | -7.29m | 3.77m | 53.00 | -- | 14.10 | -- | 0.4192 | -0.5457 | -0.5457 | 0.6781 | 0.3099 | 0.5956 | 13.13 | 3.99 | 169,733.00 | -48.39 | -88.57 | -59.91 | -121.91 | 37.65 | 44.35 | -81.25 | -113.26 | 1.63 | -- | 0.00 | -- | -26.43 | 27.92 | -18.73 | -- | 33.80 | -- |
| Altamira Therapeutics Ltd | 0.00 | -7.95m | 3.79m | 10.00 | -- | 0.3535 | -- | -- | -16.19 | -8.62 | 0.00 | 4.78 | 0.00 | 34.05 | 32.30 | 0.00 | -103.88 | -73.80 | -6,364.67 | -123.19 | -87.90 | -- | -- | -- | 1.38 | -4.37 | 0.00 | -- | -- | -- | 61.02 | -- | -- | -- |
| Navidea Biopharmaceuticals Inc | 610.00 | -8.81m | 3.81m | 11.00 | -- | -- | -- | 6,251.17 | -0.2086 | -0.0547 | 0.00001 | -0.0327 | 0.0001 | 0.1529 | 0.0066 | 55.45 | -143.97 | -169.68 | -- | -753.52 | -8,103.28 | 91.34 | -1,411,062.00 | -1,938.53 | 0.5066 | -- | -- | -- | -87.65 | -48.49 | -46.75 | -- | 63.23 | -- |
| Axim Biotechnologies Inc | 39.77k | -8.06m | 3.81m | 6.00 | -- | -- | -- | 95.91 | -0.0366 | -0.0366 | 0.0001 | -0.0311 | 0.0095 | -- | -- | 6,628.33 | -193.43 | -154.34 | -- | -390.73 | -- | -- | -20,265.75 | -36,362.71 | -- | -0.62 | -- | -- | 345.05 | -27.38 | -29.10 | -- | -- | -- |
| Evoke Pharma Inc | 5.18m | -7.79m | 3.88m | 4.00 | -- | -- | -- | 0.7495 | -2.33 | -2.33 | 1.55 | -0.7716 | 0.5476 | 0.5235 | 7.98 | 1,295,158.00 | -82.37 | -100.48 | -109.52 | -151.10 | 96.10 | -- | -150.41 | -480.52 | 2.09 | -20.56 | 2.07 | -- | 106.51 | -- | 5.25 | -- | -- | -- |
| Biostax Corp | 0.00 | -1.65m | 3.95m | -- | -- | -- | -- | -- | -0.0198 | -0.0198 | 0.00 | -0.0456 | 0.00 | -- | -- | -- | -193.36 | -75.14 | -- | -- | -- | -- | -- | -- | -- | -8.97 | -- | -- | -- | -- | 53.32 | -- | -- | -- |
| Eiger Biopharmaceuticals Inc | 15.77m | -74.96m | 3.95m | 25.00 | -- | -- | -- | 0.2507 | -50.80 | -50.80 | 10.69 | -9.77 | 0.1985 | 0.0064 | 9.19 | 630,920.00 | -94.31 | -60.25 | -186.10 | -76.51 | 99.91 | -- | -475.26 | -823.59 | 0.6809 | -22.03 | 1.54 | -- | 16.98 | -- | 22.54 | -- | 10.51 | -- |
| Kiromic Biopharma Inc | 0.00 | -24.99m | 3.97m | 31.00 | -- | -- | -- | -- | -29.21 | -29.21 | 0.00 | -3.81 | 0.00 | -- | -- | 0.00 | -171.18 | -161.49 | -- | -213.01 | -- | -- | -- | -- | -- | -15.69 | 1.87 | -- | -- | -- | -35.90 | -- | 177.42 | -- |
| Aditxt Inc | 645.19k | -32.70m | 3.98m | 47.00 | -- | 0.1963 | -- | 6.17 | -153.12 | -153.12 | 2.14 | 12.17 | 0.0233 | 0.8927 | 1.38 | 13,727.45 | -117.12 | -192.78 | -251.19 | -321.59 | -17.30 | -- | -5,020.30 | -7,208.65 | 0.2382 | -4.09 | 0.5020 | -- | -30.90 | -- | -18.11 | -- | -- | -- |
| Seelos Therapeutics Inc | 2.20m | -37.88m | 3.98m | 15.00 | -- | -- | -- | 1.81 | -8.95 | -8.95 | 0.4402 | -3.42 | 0.1564 | -- | -- | 146,866.70 | -269.01 | -180.05 | -- | -386.76 | -- | -- | -1,719.56 | -9,612.88 | -- | -- | -- | -- | -- | -- | 48.48 | -- | -- | -- |
| Reliv International Inc | 35.13m | -175.48k | 4.07m | 208.00 | -- | 0.5881 | 10.19 | 0.116 | -0.1005 | -0.1005 | 20.12 | 6.55 | 2.09 | 8.02 | 228.49 | -- | -1.05 | -4.65 | -1.47 | -6.06 | 40.90 | 41.98 | -0.4996 | -2.33 | 1.07 | -- | 0.1064 | -- | -2.94 | -9.37 | 76.65 | -- | -35.85 | -- |
| TRACON Pharmaceuticals Inc | 12.05m | -3.59m | 4.12m | 17.00 | -- | -- | -- | 0.3419 | -5.20 | -5.20 | 7.36 | -0.3655 | 0.8146 | -- | -- | 708,529.40 | -24.26 | -79.42 | -- | -177.85 | -- | -- | -29.79 | -813.81 | -- | -0.9444 | -- | -- | -- | 32.05 | 87.68 | -- | -- | -- |
| Bio Path Holdings Inc | 0.00 | -16.08m | 4.20m | 10.00 | -- | 3.76 | -- | -- | -35.76 | -35.76 | 0.00 | 0.7136 | 0.00 | -- | -- | 0.00 | -167.56 | -70.80 | -206.12 | -76.87 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -15.94 | -- | -- | -- |
| Genprex Inc | 0.00 | -30.86m | 4.22m | 26.00 | -- | 0.4428 | -- | -- | -22.93 | -22.93 | 0.00 | 4.99 | 0.00 | -- | -- | 0.00 | -172.62 | -92.06 | -207.88 | -98.32 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.99 | -- | -7.13 | -- |
| 4Cable TV International Inc | 758.68k | -3.14m | 4.24m | 0.00 | -- | -- | -- | 5.58 | -0.0624 | -0.0624 | 0.0157 | -0.0412 | 1.07 | 1.84 | 25.22 | -- | -441.73 | -82.30 | -- | -308.10 | 29.92 | -- | -414.41 | -47.62 | 0.0064 | -0.5271 | -- | -- | -0.0914 | -- | -731.54 | -- | -- | -- |
Data as of Apr 26 2024. Currency figures normalised to Aditxt Inc's reporting currency: US Dollar USD
0.24%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| UBS Securities LLCas of 31 Dec 2023 | 1.93k | 0.10% |
| Tower Research Capital LLCas of 31 Dec 2023 | 977.00 | 0.05% |
| Qube Research & Technologies Ltd.as of 31 Dec 2023 | 700.00 | 0.04% |
| Glassman Wealth Services LLCas of 31 Dec 2023 | 500.00 | 0.03% |
| IFP Advisors, Inc.as of 31 Dec 2023 | 303.00 | 0.02% |
| Natixis Investment Managers International SAas of 31 Dec 2023 | 250.00 | 0.01% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2023 | 37.00 | 0.00% |
| FSC Securities Corp.as of 30 Sep 2023 | 10.00 | 0.00% |
| Osaic Wealth, Inc. (Investment Management)as of 31 Dec 2023 | 10.00 | 0.00% |
| American Portfolios Advisors, Inc.as of 31 Dec 2023 | 1.00 | 0.00% |
More ▼
Data from 30 Sep 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
